Mayo Clinic Collaborative Research Building

Enlarge

The Story Behind the Building
Learn about Tom Hornaday, his interesting background and his commitment to cancer research and the Mayo Clinic Collaborative Research Building. Read more. (307 K)

Requires Adobe Acrobat Reader

In early 2004, ground was broken for the Mayo Clinic Collaborative Research Building, a 100,000 square foot biomedical research facility that includes space for a new Translational Genomics Institute (TGen) initiative called the Center for Translational Drug Development (TD2), shell space for the Mayo Clinic Cancer Center and available space to accommodate other research collaborations.

TD2 is a wholly owned subsidiary of TGen dedicated to translating genomics discoveries into advances in human health by developing new drugs for the prevention and treatment of cancer. TD2 will collaborate with Mayo Clinic researchers and others in the biotechnology/pharmaceutical sector to design relevant preclinical studies that are driven by the clinical trial design, and will arrange Phase-I clinical trials.

A Message From Victor F. Trastek, M.D., Chair, Board of Governors

"This new facility represents an opportunity to greatly enhance our ongoing biomedical research collaboration with colleagues at TGen and other research groups. It also supports a critical component of our mission — supporting medical research that will help patients and ultimately lead to decreasing the burden of human disease. This project is a first step in expanding the research presence on our Scottsdale campus as outlined in the recently released 40-year Master Plan."